

Special Issue

Influenza Virus and Vaccine Development

Message from the Guest Editors

Influenza is a significant public health concern. Conventional vaccines (split, subviral or recombinant vaccines) mainly target viral hemagglutinin (HA) on the surface of viral particles and elicit neutralizing antibodies to prevent influenza infections. However, influenza viruses undergo frequent antigenic drift and/or antigenic shift that often compromise influenza vaccine performance or result in seasons with vaccine mismatch and poor protection. We are calling for manuscripts detailing the mechanisms of influenza virus replication and pathogenesis and describing how this information facilitates novel vaccine development. We particularly encourage submission of manuscripts that are not limited to HA but address other viral proteins (e.g., neuraminidase, matrix protein, polymerases) and/or different vaccine formats (e.g., DNA vaccine, viral-like particle). We sincerely hope this Special Issue serves as a platform for the exchange of the latest developments in the field of influenza virus and vaccines.

Guest Editors

Dr. Ewan Plant

Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA

Dr. Hang Xie

Food and Drug Administration, Center for Biologics Evaluation and Research, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA

Deadline for manuscript submissions

closed (31 December 2020)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/40962

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).